Fingolimod significantly reduced brain volume loss in patients with relapsing-remitting multiple sclerosis: 4-year data from FREEDOMS extension study

被引：0
|
作者：
Radue, E.
Kappos, L.
O'Connor, P.
Polman, C.
Hohlfeld, R.
Calabresi, P.
Selmaj, K.
de Vera, A.
Sfikas, N.
Zhang-Auberson, L.
Francis, G.
机构：
[1] Univ Basel Hosp, CH-4031 Basel, Switzerland
[2] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[3] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[4] Univ Munich, Munich, Germany
[5] Johns Hopkins Multiple Sclerosis Ctr, Baltimore, MD USA
[6] Med Acad Lodz, Lodz, Poland
[7] Novartis Pharma AG, Basel, Switzerland
[8] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S21 / S22
页数：2
相关论文
共 50 条
  • [1] Fingolimod Reduced Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis (RRMS) Irrespective of Baseline Inflammatory Activity: Results from the Phase III FREEDOMS Study
    Radue, E.
    Kappos, L.
    de Vera, A.
    Burtin, P.
    Holdbrook, F.
    Francis, G.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (04) : 537 - 537
  • [2] Fingolimod reduces the brain volume loss in relapsing-remitting multiple sclerosis irrespective of baseline inflammatory activity: results from FREEDOMS phase III study
    Kappos, L.
    Radue, E.
    De Vera, A.
    Burtin, P.
    Holdbrook, F.
    Francis, G.
    JOURNAL OF NEUROLOGY, 2011, 258 : 47 - 47
  • [3] Fingolimod Reduces Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis (RRMS) beyond Its Anti-Inflammatory Activity: Results from FREEDOMS
    Radue, Ernst-Wilhelm
    De Vera, Ana
    Burtin, Pascale
    Holdbrook, Frederick
    Francis, Gordon
    Kappos, Ludwig
    NEUROLOGY, 2011, 76 (09) : A393 - A393
  • [4] Long-Term Safety of Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from Phase 3 FREEDOMS II Extension Study
    Vollmer, Timothy
    Jeffery, Douglas
    Goodin, Douglas
    Kappos, Ludwig
    Lublin, Fred
    Radue, Ernst-Wilhelm
    Rammohan, Kottil
    Reder, Anthony
    Agius, Mark
    Stites, Tracy
    Li, Bingbing
    Cappiello, Linda
    von Rosenstiel, Philipp
    Calabresi, Peter
    NEUROLOGY, 2013, 80
  • [5] Effect of oral fingolimod treatment on brain volume loss in patients with relapsing-remitting multiple sclerosis estimated using Bayesian methodology
    Yin, Guosheng
    Meng, Xiangyi
    Islam, M. Zahur
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 69 - 70
  • [6] Fingolimod Reduces Annualized Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis: FREEDOMS II Study Subgroup Analysis
    Goodin, Douglas
    Jeffery, Douglas
    Kappos, Ludwig
    Lublin, Fred
    Radue, Ernst-Wilhelm
    Rammohan, Kottil
    Reder, Anthony
    Vollmer, Timothy
    Agius, Mark
    Stites, Tracy
    Li, Bingbing
    Cappiello, Linda
    von Rosenstiel, Philipp
    Calabresi, Peter
    NEUROLOGY, 2013, 80
  • [7] Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients
    De Stefano, Nicola
    Tomic, Davorka
    Radue, Ernst-Wilhelm
    Sprenger, Till
    Meier, Daniela Piani
    Haring, Dieter
    Sormani, Maria Pia
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 7 : 98 - 101
  • [8] Phase III FREEDOMS study extension: long-term safety of fingolimod (FTY720) in relapsing-remitting multiple sclerosis
    O'Connor, P.
    Polman, C.
    Hohlfeld, R.
    Selmaj, K.
    Olsson, T.
    Agoropoulou, C.
    Holdbrook, F.
    Zhang-Auberson, L.
    von Rosenstiel, P.
    Kappos, L.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 223 - 223
  • [9] Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study
    Jai Perumal
    Roumen Balabanov
    Ray Su
    Roger Chang
    Laura Balcer
    Steven Galetta
    Denise I. Campagnolo
    Robin Avila
    Lily Lee
    Danette Rutledge
    Robert J. Fox
    Advances in Therapy, 2021, 38 : 3724 - 3742
  • [10] Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study
    Tourbah, Ayman
    Papeix, Caroline
    Tourniaire, Patricia
    Rerat, Karin
    Meite, Mohamed
    Durand, Barbara
    Lamy, Fabienne
    Chouette, Isabelle
    Mekies, Claude
    Aboab, Jennyfer
    Al Khedr, Abdullatif
    Carpentier, Amer Al Najjar
    Androdias, Geraldine
    Benrabah, Rabah
    Biotti, Damien
    Bohotin, Valentin
    Bonnan, Mickael
    Bonnet, Cecilia
    Boulesteix, Jean Marc
    Brassat, David
    Busson, Philippe
    Camu, William
    Castelnovo, Giovanni
    Chapuis, Stephane
    Clavelou, Pierre
    Convers, Philippe
    Coustans, Marc
    Creange, Alain
    Delassaux, Sebastien
    Diot, Eric
    Djerdi, Madjid
    Drouet, Thomas
    Delalande, Sophie Dufour
    Pottier, Corinne Dupel
    Ferriby, Didier
    Gaida, Philippe
    Gal, Guillaume
    Giraud, Pierric
    Guilloton, Laurent
    Hascar, Tijani
    Heinzlef, Olivier
    Rouaud, Violaine Jaffrenou
    Jager, Alain
    Kubler, Christophe
    Le Coz, Patrick
    Frenay, Christine Lebrun
    Maillart, Elisabeth
    Vioud, Paris Marcel Maillet
    Malkoun, Imad
    Manchon, Eric
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
12345